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ABSTRACT
Many studies have investigated the pharmacokinetics of anti-tuberculosis drugs in
patients infected with tuberculosis. However, little is known about the pharmacokinetics
of the drugs that are used in the treatment of multi-drug resistant tuberculosis (MDR-
TB). Therefore, the objective of the present study was to investigate the steady state
concentrations and the pharmacokinetics of ofloxacin, one of the drugs used in the
treatment of MDR-TB in patients infected with MDR-TB and patients with MDR-TB
co-infected with HIV
Plasma samples were drawn at different times over 24 hours after ofloxacin oral
administration. For the determination of ofloxacin plasma concentrations, the liquid
chromatography coupled with mass spectrometry analysis method was used.
The method was validated over a concentration range of 0.1-10 µg/ml. The lower limit
of ofloxacin detection was 0.05µg/ml, while the lower limit of quantification was
0.1µg/ml. The response was linear over the range used with a mean recovery of 97.6%.
Ofloxacin peak was well separated at a retention time of 9.6 minutes.
The pharmacokinetic parameters obtained were presented as mean ± standard deviation
(SD). The peak concentration of ofloxacin (Cmax) was 4.71± 2.27 µg/ml occurred at Tmax
3±1.29 hours after ofloxacin oral administration. The mean (±SD) for the area under the
concentration-time curve (AUC0-24) and the area under the concentration-time curve
(AUC0-∞) were 68.8±42.61 µg/ml.hr and 91.93±76.86 µg/ml.hr, respectively. Ofloxacin
distributed widely with a mean (±SD) volume of distribution (Vd) 2.77±1.16 L/kg and it
was eliminated with a mean (±SD) total clearance rate of 0.27±0.25 L/hr/kg. Ofloxacin
mean (±SD) half-life was 9.55± 4.69 hours and mean (±SD) of the mean residence time
(MRT) was 1512± 6.59 hours.
In summary, compared with the previous findings in the literature, ofloxacin
pharmacokinetic was altered in MDR-TB patients with or without HIV co-infection.
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The AUC and Cmax were reduced, while the half-life and the time to reach the peak
concentration were prolonged. This suggests that, both the rate and the extent of
ofloxacin absorption were decreased. Furthermore, ofloxacin was highly eliminated in
patients, which may be related to the altered liver function in this group of patients.
Further studies investigating the effect of HIV, liver and kidney dysfunctions on
ofloxacin pharmacokinetics are recommended in large number of patients infected with
MDR-TB.in addition to the therapeutic drug monitoring to maintain the desired
concentration of ofloxacin in the patients.
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1CHAPTER ONE
INTRODUCTION
Tuberculosis (TB) is a global epidemic with an estimated one third of the world’s population
being infected with Mycobacterium tuberculosis (MTB). The increase in TB cases over the
past two decades was largely attributed to the human immunodeficiency virus (HIV) infection
epidemic. According to the World Health Organization (WHO), 9.2 million new cases of TB
occurred in 2006, of which, 0.7 million cases were in HIV-positive patients (WHO, 2008).
Furthermore, the global problem of TB has been complicated by the emergence of drug-
resistant strains of MTB to the current drugs used in TB treatment regimens. Multi-drug
resistant tuberculosis (MDR-TB) refers to MTB strains that are resistant to isoniazid (INH)
and rifampicin (RIF), which are the most important first line drugs that are used in TB
treatment regimens. MDR-TB presents as an increasing threat to the global tuberculosis
control with approximately 425,000 new cases annually, representing nearly 5% of the
world’s annual TB burden (Zignol et al., 2006; Wells et al., 2007).
Based on the WHO estimations, Sub-Saharan Africa has high rates of MDR-TB burden and
South Africa is one of the most affected areas where 1.8% of the new TB cases were found to
be MDR-TB (WHO, 2008). TB low cure and high defaulting rates have resulted in a high
proportion of MDR-TB patients (6.7%) among previously treated patients in South Africa
(Weyer et al., 2004; WHO, 2008). Moreover, the high prevalence of HIV-infection is a major
determinant of MDR-TB in South Africa, and outbreak of MDR-TB among HIV infected
patients has been reported (Sacks et al., 1999). Another concern that arises is the presence of
extensively drug resistant tuberculosis (XDR-TB). This resistance is not only to the first line
drugs but also to second line drugs, which are used in the treatment of MDR-TB (Raviglione
and Smith, 2007). For example, in Kwazulu-Natal, one of the nine provinces in South Africa,
the prevalence of XDR-TB was found to be 6% among TB patients (Gandhi et al., 2006). In
addition, patients who were infected with XDR-TB were found to be HIV-positive. The data
from Kwazulu-Natal showed that, XDR-TB was transmitted to patients co-infected with HIV
and it was associated with high mortality rates (98%) and a median survival time of 16 days
 
 
 
 
2from the time of diagnosis (Gandhi et al., 2006). This raised the concern about the success of
the treatment of TB and MDR-TB, especially in patients co-infected with HIV.
Drug resistance is a result of several factors such as inadequate treatment, inappropriate
treatment regimens and poor compliance. In addition to these factors, abnormal
pharmacokinetics and poor absorption of anti-TB drugs, especially in patients co-infected with
HIV infection can be considered. The abnormal pharmacokinetics and poor absorption of
anti-TB drugs lead to sub-therapeutic concentrations of these drugs, which reduces their
effectiveness and contributes to treatment failure, relapse and acquired drug resistance
(Peloquin et al., 1996; Gurumurthy et al., 2004; Weiner et al., 2005). TB patients co-infected
with HIV may have alteration in their body system functions, which may affect the
pharmacokinetics of anti-TB drugs. Furthermore, antiretroviral drugs used in the treatment of
HIV have pharmacokinetic interactions with anti-TB drugs. This may lead to alteration in
anti-TB drugs serum concentrations (Burman et al., 1999). Therefore, the investigation of
anti-TB drugs pharmacokinetics and the use of therapeutic drug monitoring (TDM) in TB
patients and TB patients co-infected with HIV are highly recommended in order to prevent
treatment failure and further drug resistance (Yew, 2001; Peloquin, 2002).
To date, some studies have investigated the pharmacokinetic profile of first line drugs in TB
patients and TB patients co-infected with HIV (Gurumurthy et al., 2004; McIlleron et al.,
2006; Wilkins et al., 2006). However, there are few studies that describe the pharmacokinetics
of second line drugs in MDR-TB patients with or without HIV infection. For example, studies
on the pharmacokinetics of ofloxacin, which is one of the drugs used in the management of
MDR-TB, are still rare (Maranetra, 1999; Yew et al., 1999; WHO, 2003 and Chulavatnatol et
al., 2003). Moreover, to the best of knowledge, there has been no study done of the
pharmacokinetics of ofloxacin in South Africa.
Therefore, in this study, the pharmacokinetics of ofloxacin in MDR-TB patients and MDR-TB
patients co-infected with HIV was determined during their regular course of treatment. To
determine the concentration of ofloxacin, blood samples were collected from patients after
ofloxacin attained the steady state. For the determination and the quantification of ofloxacin
 
 
 
 
3concentrations, liquid chromatography/mass spectrometry (LC/MS) analysis method was used
because it has high selectivity and sensitivity (van Vyncht et al., 2002; Ballesteros et al., 2003;
Sinnaeve et al., 2003).
The rest of the thesis was organized as follows: the literature is reviewed in the second
chapter. An overview of MDR-TB and its chemotherapy are provided. The pharmacokinetics
and factors that may affect it are described. Furthermore, the pharmacokinetics of ofloxacin in
healthy volunteers and TB patients is reviewed. Methods that are used in the analysis of
ofloxacin and the determination of its pharmacokinetic parameters are also mentioned in this
chapter.
In the third chapter the study site, procedures, the methodology used in this work as well as
the method used for the quantitative analysis of ofloxacin in the patients’ samples are
described. In addition, the method used in the calculation of ofloxacin pharmacokinetic
parameters, and statistical analysis method are explained.
In the fourth chapter the results obtained are presented and discussed. The clinical and
therapeutic implications of the results are also highlighted in this chapter together with the
limitations of the present study.
In the fifth chapter the main findings of the study are summarized. Recommendations and
justification for further studies are also included.
 
 
 
 
4CHAPTER TWO
LITERATURE REVIEW
2.1 Overview of multi-drug resistant tuberculosis
2.1.1 Background
Over the past decade, there has been an increase in the appearance of strains of TB that are
resistant to anti-TB drugs. MDR-TB is caused by TB strains that are resistant to the first line
drugs INH and RIF, which are considered to be the most potent drugs against drug-susceptible
TB (Iseman, 2002; Sharma and Mohan, 2004). The molecular basis of drug resistance to TB is
now largely understood. From a microbiological point of view, the resistance is caused by a
spontaneous and random mutation in the MTB bacterial chromosome. This leads to amino
acids substitutions in their target proteins (e.g. β-subunit of MTB RNA polymerase in case of
rifampicin), which result in reduced susceptibility to specific drug, and thus, the drug,
becomes ineffective against the mutant bacilli (Blanchard, 1996; Ramaswamy and Muser,
1998).
Drug resistance is categorized into primary, acquired and initial resistance (Kochi et. al., 1993;
Loddenkemper et al., 2002). Primary resistance is resistance to anti-TB drugs in patients with
no history of previous TB treatment, i.e. treatment-naïve patients. On the other hand, acquired
resistance is resistance to anti-TB drugs from patients with previous treatment, which could be
one or more treatment. Finally, initial resistance is referred to patients with primary resistance
as well as those with undisclosed acquired resistance.
Causes of drug resistance include many factors such as inadequate treatment regimens
prescribed, poor drug supply and quality, misuse of anti-TB drugs, poor treatment compliance,
treatment default and HIV co-infection (Iseman, 1993; Jain, 1998; Sharma and Mohan, 2004).
The HIV-infection epidemic has caused an explosive increase in TB incidence and may be
contributing to the increase in MDR-TB infection. Outbreaks of MDR-TB infection and case-
 
 
 
 
5fatality rates reaching 83% among HIV-infected patients have been reported (Fischl et al.,
1992; Sacks et al., 1999; Franzetti et al., 1999). This suggests that the severe immune
suppression, which occurs in HIV infected patients, appears to be a predisposing factor for the
development of MDR-TB. During the HIV-infection, a notable reduction of CD4+
lymphocytes occurs, which leads to an increased risk of reactivation or re-infection by TB
(Havlir and Barnes, 1999). Furthermore, acquired drug resistance has been associated with the
poor absorption of anti-TB drugs in HIV-infected patients (Weiner et al., 2005; Gurumurthy et
al., 2004).
2.1.2 Chemotherapy of multi-drug resistant tuberculosis
Tuberculosis treatment consists of a combination of drugs that are considered to be first line
therapy, including INH, RIF, pyrazinamide (PZA) and ethambutol (EMB). These drugs are
used in the standardized treatment regimens, which have an initial (intensive) phase for 2
months and a continuation phase for 4-6 months (WHO, 2003). During the initial phase,
usually 4 first line drugs are used, which are INH, RIF, PZA and EMB. Then, in the
continuation phase INH and RIF are used.
Without the two potent drugs INH and RIF the treatment of TB becomes difficult, because the
drugs used in the treatment of MDR-TB are less potent and not as well tolerated as first line
drugs (Perri and Bonora, 2004). The treatment of MDR-TB infection includes an
aminoglycoside (amikacin or kanamycin), a fluoroquinolone (ofloxacin or ciprofloxacin), a
glycopeptides (capreomycin), a thiomide (ethionamide or prothionamide), cycloserine, and
para-aminosalysilic acid (Tomioka, 2000; WHO, 2003; Perri and Bonora, 2004). These drugs
are the reserve drugs for MDR-TB treatment and labeled as second line drugs. Compared with
first line drugs, second line drugs are less effective, more toxic, and costly (Perri and Bonora,
2004).
MDR-TB treatment in the developed countries is expensive and involves an individualized
regimen based on drug susceptibility data and the use of reserve drugs. By contrast, in the
resource poor countries, the WHO treatment regimens are used in addition to directly
observed treatment (DOT) based regimens, which are supporting the national TB programmes
 
 
 
 
6(Ormerod, 2005). In South Africa, the guidelines for MDR-TB treatment have been drawn
from the WHO guidelines. There are two regimen approaches, the first one is a standard
treatment regimen and the second one is an individualized treatment regimen (Weyer, 1999).
The standard treatment regimen consists of 4 months intensive phase with five drugs
(kanamycin, ethionamide, pyrazinamide, ofloxacin and ethambutol) followed by a continuous
phase of 12-18 months with 3 drugs (ethionamide, ofloxacin and ethambutol). The drugs used
in the two phases and the dosages of these drugs are given in Table 2.1 and Table 2.2 (Weyer,
1999; Department of health, South Africa, 2006).
 
 
 
 
7Table 2.1: Second line anti TB-drugs used in the intensive phase (4 months) in South Africa
(Weyer, 1999; Department of health, South Africa, 2006).
Drug Daily dosage (mg)
Kanamycin 750-1000
Ethionamide 500-750
Pyrazinamide 1000-1500
Ofloxacin 600-800
Ethambutol 800-1200
Table 2.2: Second line anti TB-drugs used in the continuation phase (12-18 months) in South
Africa (Weyer, 1999; Department of health, South Africa, 2006)
Drug Daily dosage (mg)
Ethionamide 500-750
Ofloxacin 600-800
Ethambutol 800-1200
 Terizadone is used if the strain is resistant to ethambutol.
 Kanamycin may be substituted with amikacin.
 Ofloxacin may be substituted with ciprofloxacin.
 
 
 
 
8MDR-TB treatment is complicated and frequently associated with treatment failure, relapse
and high incidences of adverse drug reactions, which lead to prolonged illness, disability and
death as a consequence (Goble et al., 1993; Cohn, 1995; Flament-Saillour et al., 1999).
Nevertheless, cure with appropriate intensive MDR-TB treatment regimens has been reported.
Starting treatment early with regular follow up, using aggressive treatment regimens and
improving treatment adherence with DOT may result in high cure rate reaching 75% (Park et
al., 1998; Mukherjee et al., 2004; Edward et al., 2004; Leimane et al., 2005).
Treatment of MDR-TB in patients co-infected with HIV is associated with poor outcomes and
high mortality rates of 72-89% (Cohn, 1995). Deaths during treatment caused by MDR-TB
infection or by other HIV-related diseases are more frequent, particularly, in the advanced
HIV-infection stages (Cohn, 1995). However, starting treatment early may increase the
survival time in HIV patient co-infected with MDR-TB (Edlin et al., 1993; Franzetti et al.,
1999). By contrast, HIV-negative patients with MDR-TB have good response to appropriate
MDR-TB chemotherapy regimens with 64% outcome of completing the course of therapy and
no relapse (Telzak et al., 1995; Kwon et al., 2008).
The optimum duration of MDR-TB treatment is still unknown. The recommended duration of
treatment is guided by sputum smear/culture conversion to negative. The minimal
recommendation is that treatment should last for at least 18 months after culture conversion.
However, patients resistant to all or most of the first line drugs and patients co-infected with
HIV have been treated for 2 years after cultures convert to negative to prevent relapse
(Iseman, 1993; Pozniak, 2001). In South Africa, prolonged treatment is required in MDR-TB
patients and it is usually for at least 18 months (Department of health, South Africa, 2006).
2.2 Pharmacokinetics
2.2.1 Overview
The pharmacokinetics of each drug describes the fundamental processes of its disposition,
namely its absorption, distribution, metabolism and elimination. Moreover, it describes the
resulting concentration versus time profile of the administered drug. These processes of
 
 
 
 
9absorption, distribution, metabolism and elimination determine how rapidly, in what
concentration and for how long the drug will appear in the target organ (Grahame-Smith and
Aronson, 1991).
The key principle to understand a drug’s pharmacokinetics is by determining the PK
parameters of such a drug in the blood and/or urine. These parameters are the result of the
fundamental processes of the disposition, which influence the drug concentration inside the
body.
2.2.2 Pharmacokinetic parameters
The drug concentration-time profile is studied by the means of several PK parameters .The
basic PK parameters, which were used in the present study and quantitatively describe a drug
PK are Cmax, Tmax, AUC, T½, Ke, MRT, Cl and Vd. These pharmacokinetic parameters are
defined as follows:
Cmax (also known as the peak height) is the maximum concentration of the drug in blood
plasma achieved
Tmax is the time after drug administration at which the maximum (peak) plasma concentration
occurs, i.e. the time taken to reach Cmax.
AUC is the area under the plasma concentration-time curve. It is the overall amount of drug in
blood stream after a dose.
T½ is the plasma half-life. It is the time taken for the drug plasma concentration levels to fall
by 50%.
Ke is the drug’s elimination rate constant.
MRT is the mean residence time. It is the average time that the drug molecules spend in the
body.
Cl is the drug clearance. It is the measure of the body ability to eliminate drug. The total body
systemic clearance (Cltot) of a drug is the sum of the clearances of the drug by various organs
and tissues of the body.
Vd is the drug apparent volume of distribution. It is the measure of the available apparent
space in the body that is available to contain the drug.
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Cmax, Tmax and AUC express the drug bioavailability, which is the proportion of the
administered drug that reaches the systemic circulation. Cmax and Tmax are used to measure
drug’s absorption rate, while the AUC is used to measure the total amount of drug absorbed in
the body (Grahame-Smith and Aronson, 1991). T½ is a useful pharmacokinetic parameter, as
it indicates the time required to attain 50% of the steady state or to decay from the steady state
condition. In addition, it shows the rate of accumulation of the drug in the body during
multiple dosing, which helps with the dosing of the drug (Grahame-Smith and Aronson,
1991). Vd helps in planning dose regimens, interpretation of drug interaction and relating the
T½ to the total Cl. Increasing Vd indicates that, the drug has a much higher concentration in
the extra-vascular tissues than in the vascular parts, which means it is not homogenously
distributed. The Cltot is, like the half-life, used to quantify drug elimination. Knowing a drug
Cl helps in assessing the drug excretion mechanisms and calculating the dosage regimen.
By studying the pharmacokinetic parameters of a drug, one can define its processes of
absorption, distribution, metabolism and elimination. Moreover, the proper mathematical
description of the pharmacokinetic parameters of the drug provides information related to its
pharmacological, therapeutic and/or toxic effects.
2.2.3 Factors affecting the pharmacokinetics of a drug
There are many factors that can affect the pharmacokinetic parameters of a drug, and thus,
change its pharmacokinetic profile. Such factors include age, gender, body weight, genetic
factor, food administration, diseases and various drug-drug interactions (Gibaldi, 1991;
Katzung, 1998). Distribution and elimination of many drugs change as a function of the age.
The half-life and apparent volume of distribution of a drug differ with different age groups
(new born, infant, children, adults and elderly). Different body weights lead to different
distribution volumes, which result in different drug concentrations in the plasma. The genetic
factor is also a major cause of differences in the drug plasma concentrations and the rate of
clearance. Drug-drug interactions have pharmacokinetic bases by affecting absorption,
distribution, metabolism or elimination of a drug and its pharmacokinetic parameters as a
consequence.
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Diseases affect normal functioning of the gastrointestinal tract (GIT), renal and hepatic
systems have influence on the PK of many drugs. Diseases affecting the GIT may affect drug
absorption, Cmax, Tmax and as a consequence AUC. Liver diseases have a great impact on
pharmacokinetics of drugs that are metabolized in the liver, which results in longer T½, and
reduced clearance of these drugs and thus lead to toxicity. Diseases changing renal functions
have the greatest effect on the pharmacokinetics of drugs eliminated unchanged mainly via
renal clearance. The clearance of such drugs decreases and their T½ will increase and may
lead to toxicity (Gibaldi, 1991). Some pathological states such as oedema, ascites and pleural
effusion are associated with abnormal accumulation of fluids, which increases the Vd of drugs
(Katzung, 1998).
2.2.4 Effect of HIV on drug pharmacokinetics
HIV-enteropathy and other AIDS associated opportunistic infections affect many organ
systems involved in drugs pharmacokinetics e.g. the GIT, liver and kidney. The GIT is the
main part of the body that is responsible for the drug absorption and any dysfunction results in
drug malabsorption. Candidiasis, colitis, Kaposi’s sarcoma and stomatitis are some of the
diseases that occur frequently in patients infected with HIV and influence the GIT system
normal functions (Unadkat and Agosti, 1990). In addition, diarrhea is one of the most
common GIT symptoms reported in HIV patients and may result in drug malabsorption
(Pillai, 1998). Moreover, the pH of the stomach is higher in AIDS patients, and it is known
that, the pH at the absorption sites is an important factor in the drug absorption and thus, any
change in the stomach pH affect drugs absorption (Unadkat and Agosti, 1990; Gibaldi, 1991).
Liver is an important organ of drug metabolism, and any dysfunction of the liver may lead to
changes in the drug metabolism. Liver diseases and intra-hepatic opportunistic infections
occur frequently in patients infected with HIV. These diseases include hepatitis,
Mycobacterium avium complex, Kaposi’s sarcoma, lymphoma and biliary disease (Bartlett
and Gallant, 2004).
Kidneys play an important role in the drug elimination through glomerular filtration, renal
tubular secretion and reabsorption, which is going via a high capacity transport system that
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plays a major role in drugs and/or metabolite excretion. The transport system has many
transporters families e.g. P-glycoprotein (P-gp) family and the multi-drug resistant associated
proteins (MRP) (Launay-Vacher et al., 2006). These transporters play an important role in the
drugs secretion and/or active reabsorption mechanisms that is responsible of drugs excretion.
Diseases affecting renal system alter transporter proteins activity and contribute significantly
to the change in drug’s PK, tolerance and efficacy. This results in renal toxicity and systemic
accumulation of drugs (Launay-Vacher et al., 2006). As an example, P-gp functions decreased
in renal failure and contribute to the decrease in drug clearance (Sun et al., 2005; Launay-
Vacher et al., 2006). Renal diseases occur often in AIDS patients. These diseases include
nephropathy; HIV-infection associated glomerulonephritis and proteinuria in addition to fluids
and electrolyte imbalances (Unadkat and Agosti, 1990, Bartlett and Gallant, 2004).
2.3 Laboratory findings in cases of hepatic and/or renal dysfunctions
Liver function tests (LFT) measure the concentration of various different proteins and
enzymes in the blood that are either produced by the liver cells or released when the liver cells
are damaged. The liver function tests that assess the ability of the liver to eliminate substances
that undergo hepatic metabolism such as 14C-aminopyrine breath test are limited by
complexity and availability (DiPiro et al., 2008). Routine liver tests include measuring
bilirubin, aspartate transaminase (AST), alanine transaminase (ALT) and gamma glutamyl
transpeptidase (GGT) levels in the blood. AST and ALT are enzymes located in the cytoplasm
of hepatocytes, while GGT found in bile ducts and their levels will be elevated with
hepatocellular injury and viral hepatitis (Giannini et al., 2005). The degree of elevation of
these enzymes is helpful in suggesting possible etiologies. The highest levels (> 20 fold
increase above normal) are seen in acute drug induced viral infections e.g. hepatitis or
ischaemic events associated with circulatory catastrophes such as a stroke or myocardial
infarction. Liver function tests will typically be evaluated in chronic inflammatory liver
disease such as hepatitis, biliary obstruction, alcoholic hepatitis and ischemic and toxic
injuries (Giannini et al., 2005; DiPiro et al., 2008).
The renal functions include processes of filtration, secretion, and reabsorbtion as well as
endocrine and metabolic functions. Renal function is generally assessed by measuring serum
 
 
 
 
13
creatinine and urea levels, or calculation of the glomerular filtration rate (GFR). The GFR is
used to categorize the stages of kidney function, which range from normal renal function in
case of GFR > 90 ml/min to renal failure in case of GFR < 15 ml/min (DiPiro et al., 2008).
2.4 Pharmacokinetics of anti-tuberculosis drugs in HIV patients
2.4.1 Absorption of anti-tuberculosis drugs in patients co-infected with HIV
Anti-TB drugs poor absorption has been reported in HIV-infected patients with association to
the HIV-enteropathy. The poor absorption of anti-TB drugs results in drug sub-therapeutic
serum concentration levels, treatment failure, relapse, and acquired drug resistance (Patel et
al., 1995; Peloquin et al., 1996; Weiner et al., 2005).
In the literature, some studies have investigated the absorption of anti-TB drugs in HIV-
infected and non HIV-infected patients. Many studies of TB patients co-infected with HIV
have yielded similar results. In a study done by Peloquin et al. (1996) it was found that, anti-
TB drugs serum (peak) concentrations were lower in TB patients co-infected with HIV and
having CD4 cell count <200 cell/mm³. Another study showed that, total systemic
concentrations were reduced by 32% for RIF and 24% for PZA in HIV-infected patients
compared to the healthy control group, which was probably related to the poor absorption of
these drugs in HIV infected patients (Sahai et al., 1997). In Botswana, low serum
concentration of INH, RIF and EMB (with delayed absorption of EMB and RIF) in HIV-
positive patients infected with TB have also been reported (Tappero et al., 2005). By contrast,
a study found no differences between HIV-positive and HIV-negative patients with
tuberculosis, in terms of concentration levels or total absorption of INH, PZA or RIF
(Choudhri et al., 1997). This last study by Choudhri et al., 1997 indicates that, the prevalence
and clinical significance of poor absorption of anti-TB drugs in TB patients co-infected with
HIV remain controversial. However, measuring TB drug levels remain strongly considered for
preventing the poor absorption, which lead to treatment failure and acquired drug resistance
(Yew, 2001; Peloquin, 2002).
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2.4.2 Interactions between anti-tuberculosis and anti-retroviral drugs
Immunocompromised patients are at high risk of drug-drug interactions during their TB
treatment. The drug-drug pharmacokinetic interactions between antiretroviral (ARV) drugs
and anti-TB drugs have been reported in the literature (Lopez-Cortes et al., 2002; Hamzeh et
al., 2003; Winston and Boffito, 2005). For first line anti-TB drugs, the major drug–drug
interaction occurs between RIF and the highly active anti-retroviral therapy (HAART) drugs
particularly, the protease inhibitors (PIs) and the non-nucleoside reverse transcriptase
inhibitors (NNRTIs) (Burman et al., 1999; Aaron et al., 2004). RIF is an enzyme inducer; it
induces the cytochrome P450 (CYP450) enzyme system in the liver, which leads to a decrease
in the concentrations of PIs and NNRTIs to sub-therapeutic levels
These interactions cause a problem, because the standard short-course regimens for TB
therapy are based on RIF and should be used wherever possible. There are many
recommendations in the treatment of TB patients who are co-infected with HIV. Some
guidelines recommend modification to the TB therapy or HIV-infection treatment drugs
(Pozniak et al., 1999). Modification of antiretroviral drug dosage or the use of alternative TB
treatment regimens, which do not include rifampicin, have also been recommended (Havlir
and Barnes, 1999; Aaron et al., 2004).
In addition to the interaction with ARV drugs, some anti-TB drugs interact with drugs that are
used in treatment of AIDS associated opportunistic infections. Rifampicin clinical interactions
with anti-infective such as chloramphenicol and doxycycline, anticoagulants, antacids and
glucocorticoids have been reported (Yew, 2002).
Most of the second line drugs that are used in MDR-TB treatment regimens have not had
drug/drug interaction studies performed with HIV-infection treatment compounds, although
the potential for adverse interactions is considerable. There are major overlapping toxicities
especially those causing hepatic reactions. Therefore, an intensive management and
monitoring is required for these patients (Pozniak, 2001).
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Therapeutic drug monitoring (TDM) which is the measurement of the drug concentration in
the plasma, can enable better management of anti-TB drugs malabsorption in addition to their
interactions with ARV drugs in order to maintain relatively constant concentrations in the
blood stream. By measuring the drug levels in the blood at intervals, TDM maintains TB
drugs plasma concentrations within the therapeutic range and it prevents toxicity from high
doses or treatment failure from low doses, which may lead to relapse and drug resistance.
The TDM of anti-TB drugs in TB patients is highly recommended (Yew, 2001; Peloquin,
2002). It allows better control of TB treatment, particularly in MDR-TB patients and in
patients with co-morbid conditions such as HIV, liver and kidney dysfunctions. TDM helps in
managing anti-TB drugs interactions and poor absorption, which are correlated with the low
concentration of anti-TB drugs, especially in TB patients co-infected with HIV (Peloquin,
2002; Li et al., 2004).
2.5 Ofloxacin pharmacology and pharmacokinetics
2.5.1 Overview
Ofloxacin is a bactericidal, broad-spectrum antimicrobial agent and belongs to the
fluoroquinolone antibiotic group. It is a synthetic fluorinated derivative of nalidixic acid and
classified as second-generation fluoroquinolone.
2.5.2 Ofloxacin antimicrobial spectrum of activity and mechanism of action
Ofloxacin has a broad antibacterial spectrum in vivo and in vitro with activity similar to that of
other fluoroquinolones. It is active against a wide range of gram-negative and gram-positive
bacteria. Moreover, ofloxacin has antibacterial activity against intracellular pathogens such as
Legionella, Chlamydia and mycobacteria including Mycobacterium avium complex and
Mycobacterium tuberculosis (Walker, 1999).
Ofloxacin mechanism of action is based on the inhibition of the bacterial enzyme DNA
gyrase, which is responsible for coiling the genetic material as prerequisite for bacterial
multiplication (Walker, 1999).
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2.5.2.1 Activity against Mycobacterium tuberculosis
Many in vitro studies reported that ofloxacin has relatively potent activity against MTB and
other species of mycobacteria e.g. Mycobacterium kansasii and Mycobacterium avium
complex (Vacher et al., 1999). Ofloxacin is active against drug resistant Mycobacterium
tuberculosis with 2µg/ml as a minimum inhibitory concentration for 90% (MIC90) of tested
strains, other studies demonstrated the activity of fluoroquinolones including ofloxacin within
human macrophage, where many tubercle bacilli reside (Wise and Honeybourne, 1999, Ruiz-
Serrano et al., 2000). In addition, the antimycobacterial effect of low, non-bactericidal
concentration of ofloxacin within the macrophage is enhanced by the presence of PZA, which
is important for the use of these agents in TB preventive combination regimens (Jacobs, 1999;
Berning, 2001).
2.5.3 Ofloxacin pharmacokinetics
In addition to the wide spectrum of activity of ofloxacin as an antimicrobial drug, it has a
good pharmacokinetic. This makes ofloxacin suitable and preferable to be used in the
treatment of many diseases including urinary tract infections, prostatitis, respiratory tract
infections, gastrointestinal and abdominal infection (Katzung, 1998, Walker, 1999; Turnidge,
1999).
2.5.3.1 Absorption
Ofloxacin is well absorbed and has high oral bioavailability. The oral version of ofloxacin
absorption is very high and reaches 95% with a peak serum concentrations reached within 1-2
hours (Walker, 1999). The blood levels achieved with ofloxacin oral administration are
similar to those obtained after intravenous route of administration, which makes a benefit in
conversion from intravenous route to oral therapy (Yuk et al., 1991; Walker, 1999).
Ofloxacin absorption may be blocked by divalent cations included in nutritional supplements
and antacid. Co-ingestion with food also delays absorption and as a consequence the time to
reach the peak serum concentration delays by one hour (Katzung, 1998, Walker, 1999).
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2.5.3.2 Distribution
Ofloxacin penetrates most tissues well e.g. bronchial mucosa, lung, kidney, gall bladder and
genital tract. It is widely distributed including intracellular fluids and has a high volume of
distribution generally > 150 liters. This may be due to ofloxacin low protein binding which is
less than 30% (Walker, 1999; Wise and Honeybourne, 1999). The wide distribution and good
tissues penetration of ofloxacin is advantageous for treatment of disseminated TB (Gilks et al.,
1990).
2.5.3.3 Metabolism and elimination
Ofloxacin undergoes metabolism. Between 65% and 80% of an administered oral dose of
ofloxacin is excreted unchanged via the kidneys within 48 hours of dosing. The unchanged
form is excreted mainly by the kidney (Walker, 1999; Wise and Honeybourne, 1999). In the
case of patients with impaired renal function (creatinine clearance ≤ 50 ml/min), ofloxacin
elimination decreases and it accumulates. This leads to the increase of its T½. Therefore, dose
adjustment in patients with impaired renal function is required.
2.5.4 Ofloxacin drug-interactions
As other fluoroquinolones, the main drug interaction of ofloxacin is the impaired absorption
by co-administration of multivalent metal cations, which are included in antacids, nutritional
supplements, dairy products (calcium), some haematinics (iron) and sucralfate. This may lead
to the decrease in AUC and Cmax of ofloxacin. Thus, ofloxacin should be administered at least
two hours before these cationic compounds are administered (Katzung, 1998, Walker, 1999;
Yew, 2002). Probenecid may interfere with the renal clearance of ofloxacin, which may result
in an increase in the half-life of ofloxacin. In addition, elevated serum levels of cyclosporine
have been reported with concomitant use of cyclosporine with some other fluoroquinolones.
Regarding anti-retroviral drugs, the main interaction occurs with didanosine, which contains
buffering agents such as magnesium and aluminum salts in its formulation that lead to a
chelation base interaction. This interaction leads to a decrease in ofloxacin absorption and as a
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consequence it’s AUC. However, this interaction can be avoided by separating administration
of ofloxacin and didanosine by at least 2 hours (Goodman et al., 2005)
2.5.5 Safety, adverse effects and precautions
Ofloxacin is well tolerated and safe. The most common adverse effects include
gastrointestinal upset and central nervous system symptoms. GIT adverse effects include
nausea, vomiting and diarrhea. Central nervous system symptoms occasionally experienced
are headache, dizziness and insomnia. Allergic reactions such as skin rash, urticaria and
photosensitivity occur in 1-2% of patients (Katzung, 1998, Walker, 1999). Ofloxacin as other
fluoroquinolones is contraindicated during pregnancy, breast-feeding. It should be used with
caution in patients with cerebral convulsive disorders, and careful monitoring is required in
patients with impaired renal or hepatic functions
2.5.6 Ofloxacin clinical uses
Ofloxacin is used in many infections such as urinary tract infections, prostatitis,
gastrointestinal and abdominal infections, bone, joint and soft tissue infections, gonorrhoea,
skin infections, and respiratory tract infections including sinusitis (Walker, 1999, Goodman et
al., 2005).
2.5.6.1 Use of ofloxacin in multi-drug resistant tuberculosis
The favorable microbiological, pharmacokinetic, toxicity and drug interaction profile of
ofloxacin makes it a promising agent in the treatment of the respiratory tract infections and in
the treatment of MTB infection (Wise and Honeybourne, 1999). Today, ofloxacin is used for
prevention therapy, empirical treatment of patients with TB and retreatment of patients with
MDR-TB (Berning, 2001). Furthermore, ofloxacin is reported to be safe and effective when it
is used in MDR-TB combination treatment regimens with treatment success rate of 78%
(Maranetra, 1999; Montoya et al., 1999).
In South Africa, ofloxacin is one of the second line drugs that are used in MDR-TB treatment
regimens. It is used in the standard treatment regimens, in the intensive phase and the
continuation phase (Weyer, 1999; Department of health, South Africa, 2006). The dose of
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ofloxacin depends on the patient's weight with an average of 7.5-15 mg/kg and a maximum
daily dose of 800 mg.
2.5.7 Resistance to fluoroquinolones and ofloxacin
The fluoroquinolones’ wide use for many infections leads to a selective pressure on these
broad-spectrum agents. This results in the emergence of fluoroquinolone resistance in a
diversity of organisms including MTB. The primary mechanism of fluoroquinolone resistance
in MTB thus far, is related to the mutation in the DNA gyrase (gyr A) gene (Ramaswany and
Musser, 1998). There are no reports of cross-resistance between fluoroquinolones and other
classes of anti-TB drugs. However, cross resistance within the fluoroquinolone class agents
occurs. Therefore, susceptibility reduction to one fluoroquinolone likely confirms
susceptibility reduction to all other fluoroquinolones (Ginsburg et al., 2003).
Resistance to ofloxacin in MDR-TB patients is reported in the literature (Grimaldo et al.,
2001; Ginsburg et al., 2003; Shi et al., 2006; Umubyeyi et al., 2007). Ofloxacin resistance
develops rapidly when it is used alone against MTB or when it is added singly to a failing
therapy regimen. Co-infection with HIV may also be associated with development of
ofloxacin resistance, especially in individuals with advanced AIDS and it was reported in
patients with CD4+ cell count < 50 cell/ mm3 (Perlman et al., 1997; Ginsburg et al., 2003).
The rapid proliferation of MTB for long period of time in HIV patients with decreased cell
mediated immunity can be associated with the CD4+ cell lymphocyte levels. The low
CD4+cell levels accelerate the acquisition of resistance.
2.5.8 Ofloxacin pharmacokinetic parameters
2.5.8.1 Pharmacokinetic parameters in healthy volunteers
Ofloxacin pharmacokinetics is well known and described in the literature. Many studies have
been done to investigate ofloxacin pharmacokinetic parameters with different doses and
different ways of administration as oral, intravenous, and rectal administration (Lode et al.,
1987, Warlich et al., 1990; Yuk et al., 1991; Guay et al., 1992, Eboka et al., 1997, Immanuel
et al., 2002). Ofloxacin pharmacokinetic parameters in healthy volunteers after oral
administration are summarized in Table 2.3.
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Ofloxacin exhibits dose-independent pharmacokinetics. However, an increase in ofloxacin
Cmax and AUC with 800 mg dose compared to 600 mg dose has been reported (Immanuel et
al.,2002).
 
 
 
 
Table 2.3 Ofloxacin pharmacokinetic parameters in healthy volunteers after different oral doses.
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Dose
(mg)
Cmax
(µg/ml)
Tmax
(hr)
T½
(hr)
AUC0-24
(µg/ml.hr)
AUC0-∞
(µg/ml.hr)
CLtot
(ml/min)
Vd
(L)
Reference
200 2.96±0.30 1.9±0. 5 6.6±0.1 NA NA 188±5.5 NA Warlich et al.,
1990
400 3.14±0.53 1.74±0.57 5.48±0.81 NA 28.36±4.32 NA NA Yuk et al.,
1991
600 8.0
(7.4-8.6)
1.4
(1.0-1.8)
6.7
(6.2-7.2)
60.8
(54.2-67.4)
67.9
(60.9-74.9)
149
(135-163)
86
(78-94)
Immanuel et al.,
2002
 21
ax=maximum concentration; Tmax= time to attain Cmax; T½ = half-life; AUC0-24=area under the concentration-time curve from zero
24 hrs; AUC0-∞= area under the plasma concentration-time curve from zero to infinity, Vd = volume of distribution; Cltot = total
dy clearance
800 9.8
(8.2-11.4)
1.9
(1.6-2.2)
6.5
(6.1-6.9)
85.3
(69.4-101.2)
93.1
(79.7 -106.5)
147
(128-166)
83
(72-94)
Immanuel et al.,
2002
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2.5.8.2 Pharmacokinetic parameters in patients with tuberculosis
The pharmacokinetic properties of ofloxacin in patients with MDR-TB infection and MDR-TB
patients co-infected with HIV have not been studied extensively globally. However, there are
some studies that evaluated ofloxacin pharmacokinetic parameters in TB patients. The results of
these studies are summarized in Table 2.4.
Ofloxacin pharmacokinetics in TB patients is reported to be similar to that reported in healthy
volunteers studies, although; a delay in ofloxacin absorption in TB patients compared to healthy
volunteers has been reported (Zhu et al., 2002; Chulavatnatol et al., 2003)
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Table 2.4: Ofloxacin pharmacokinetic parameters in patients with tuberculosis
Dose
(mg)
Cmax
(µg/ml)
Tmax
(hr)
T½
(hr)
AUC0-24
(µg/ml.hr)
AUC0-∞
(µg/ml.hr)
Vd
(L/kg)
Cltot
(L/h/kg)
Reference
600 8.52 2 5.70 NA NA 1.25 0.14 Zhu et al.,2002
800 10.5 1.03 7.34 NA NA 1.28 0.12 Zhu et al.,2002
590.9mg
(mean dose) 9.61±2.1 1.68±1.2 8.03±3.3 70.57±26.4 82.45±43.64 1.37±0.24 NA Chulavatnatol et al.,
2003
600-1000 4.92±1.4 1-2 7.8 NA NA NA NA Yew et al.,1999
Cmax = maximum concentration; Tmax= time to attain Cmax; T½ = half-life; AUC0-24=area under the concentration-time curve from zero
to 24 hrs; AUC0-∞= area under the plasma concentration-time curve from zero to infinity, Vd= volume of distribution; Cltot = total body
clearance; Ke= elimination rate constant.
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2.6 Determination of anti-tuberculosis drugs concentrations
2.6.1 Methods used to determine plasma concentrations
Pharmacokinetics and therapeutic drug monitoring studies represent one of the
reasons for development of clinical assay methodologies. The literature reveals
several efficient methods and techniques for the analysis of anti-TB drugs in the
biological fluids. These analysis methods can be either non-chromatographic such as
microbiological, spectral and fluorometric assay methods or chromatographic
methods like gas and liquid chromatography.
Although microbiological assays are simple, reproducible and do not require highly
technical equipment, they are time consuming, and they lack sensitivity and
specificity (Auten et al., 1991, Immanuel and Kumar, 2001). In the spectral analysis
methods, the determination of the drug is based on its spectral absorption
measurements. In fluorometric analysis the determination is based on absorption and
re-emission of the radiation that the drug is exposed to. Some drugs do not have the
absorption or emitting properties, therefore; some complexing agents are used to
enhance spectral absorption or re-emission of these drugs. Chromatographic methods
are based on the separation in which the drug and/or the material under analysis are
distributed between two phases a stationary and a mobile phase, which move in a
definite direction. Different chromatographic methods including gas and liquid
chromatography for anti-tuberculosis drugs analyses have been reported in the
literature (Holdiness, 1985).
2.6.1.1 Liquid chromatography/mass spectrometry
The high performance liquid chromatography (HPLC) technique has been the
mainstay for anti-TB drugs bioanalytical measurements. These include quantitative
measurement of the drug and qualitative differentiation between the parent drug, its
metabolites, as well as unknown endogenous components in the analysis samples.
Multiple approaches using HPLC coupled with UV, fluorometric or mass
spectrometric detection have been used to quantify ofloxacin and other anti-TB drugs
(Holdiness, 1985; Niessan, 1998; Gennaro et al., 2001; Khuhawar and Rind, 2002).
Although there are many application areas where HPLC coupled with UV or
fluorescence detection still provides satisfactory results, there is a growing need for
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better analytical capabilities. Conventional UV and fluorescence spectroscopic
detectors have limited specificity and thus, it may be difficult to differentiate the
analyzed drug and its metabolites from endogenous matrix components. As a result,
it is important to carry out more thorough sample preparation and/or extend the
HPLC run time to allow sample extract matrix components to be resolved
chromatographically from the analyte of the interest, which consume a lot of time
(Brewer and Henion, 1998). Another reason is that, some drugs are very potent and
administered at lower doses and thus are present at much lower levels in biological
samples. Therefore, higher sensitivity and selectivity capabilities are needed, which
are not provided by HPLC/UV or fluorescence techniques for determination of drugs
and/or their metabolites in complex biological samples. Recently, liquid
chromatography coupled with mass spectrometry has become the most popular
approach in pharmacokinetics studies because mass spectrometry provides high
specificity, selectivity, and sensitivity detection, which makes it capable of accurate
quantitative analysis of drugs and their metabolites (Want et al., 2003; Kostiainen et
al., 2003).
2.6.2 Determination of ofloxacin plasma concentrations
Several methods for the determination of ofloxacin concentration in the biological
fluids have been reported in the literature, and both chromatographic and non-
chromatographic methods have been used (Horstkotter and Blaschke, 2001; Ev and
Schapoval, 2002; Garcia et al., 2002; Du et al., 2004). HPLC is the method most
commonly used for the determination and assay of ofloxacin. Other methods
including spectrophotometric, fluorometric electrophoresis and electro-analytic
methods have also been used for the determination of ofloxacin. Despite their
sensitivity, accuracy and selectivity, these methods are complicated in sample
preparation and/or separation, because they require formation of ofloxacin
complexes as in spectrophotometric and spectrofluorometric methods (Garcia et al.,
2002; Du et al., 2004).
HPLC coupled with UV and fluorescence detection are the most commonly used
methods for the determination of ofloxacin and other fluoroquinolones in biological
samples. There are few studies, which used liquid chromatography coupled with
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mass spectrometry for the determination and confirmation of ofloxacin in biological
samples. LC/MS shows high sensitivity and selectivity (van Vyncht et al., 2002;
Sinnaeve et al., 2003; Ballesteros et al., 2003).
In this study, HPLC was used for the assay of ofloxacin plasma concentrations in
patients. Chapter three has more details about the methods, chemicals used and the
LC/MS settings.
2.7 Research questions
Firstly, a study comparing all the above mentioned analysis methods would be
useful. Due to time and budget constraint, it was decided to focus on LC/MS in this
study in order to find whether LC/MS is a specific, accurate, sensitive and
reproducible method in the determination of ofloxacin plasma concentrations as
mentioned above.
Secondly, so far no study has been done on the PK of ofloxacin in MDR-TB patients
in South Africa. Therefore, it would be interesting to find out if there are any
differences or similarities between our PK data and findings from studies done
before. Furthermore, it is important to find out whether HIV infection has any
influence on ofloxacin PK.
2.8 Objectives of the study
The objectives of the present study are:
 To determine the plasma concentrations of ofloxacin using LC/MS as an
analysis method.
 To investigate the pharmacokinetics of ofloxacin in MDR-TB patients and
MDR-TB patients co-infected with HIV.
 To find out if HIV infection influences the PK of ofloxacin.
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CHAPTER THREE
METHODS
3.1 Study site
The study was conducted (from January-July 2008) at Brooklyn Chest Hospital
(BCH) in Cape Town, Province of Western Cape; South Africa. BCH is one of the
South African hospitals specialized in the treatment of MDR-TB.
3.2 Patient selection
Male and female patients involved in this study were selected from other patients
admitted at BCH using the criteria listed below.
3.2.1 Inclusion criteria
A patient was included in the study only if he/she complied with all the following
five criteria:
1. MDR-TB sensitive to second line anti-TB drugs.
2. Adult patients (18-65 years).
3. On ofloxacin therapy for at least two weeks.
4. Signature of informed written consent form, after receiving explanation of the
aims, procedures, advantages and disadvantages of the study in his/her first language
(Appendix A and B).
5. Informed Consent for HIV-testing.
3.2.2 Exclusion criteria
A patient was excluded from the study in case one or more of the following criteria
applied.
1. Patient request.
2. Pregnancy or breast-feeding.
3. Intolerance or hypersensitivity to ofloxacin.
4. Patients on drugs other than anti-retroviral drugs, known to interact with ofloxacin
pharmacokinetic (medications containing cations, such as antacid or nutritional
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supplements).
3.3 Clinical examination
Clinical examination of the patients was conducted as part of the routine care. For
each patient, the body weight was checked every day. Vital signs were recorded
every morning and evening. Patient’s complaints including reactions to medications,
if any, were recorded and assessed. Therapeutic effects were also determined for
each patient.
3. 4 Laboratory tests
The following laboratory tests were done at PathCare laboratory (Pathcare Park,
Neels Bothma Street, N1 city Good Wood, Cape Town; South Africa) in order to
assess the kidney and liver function and to determine the haematological profile of
the patients.
3.4.1 Liver function tests (LFT)
Liver function was evaluated by measuring the liver enzymes: alanine transaminase
(ALT), aspartate transaminase (AST), gamma glutamyl transpeptidase (GGT) and
bilirubin.
3.4.2 Kidney function tests (KFT)
Kidney function was evaluated by calculating the glomerular filtration rate (GFR)
from the serum creatinine using the modification of diet in renal disease (MDRD)
study following formula
GFR = 175 x (standardized SCr)-1.154 x (age)-0.203 x (0.742 if female) x (1.210 if
black).
SCr = serum creatinine.
Although MDRD equation is commonly used for estimating the GFR, it has not been
validated in indigenous African population. Therefore, black ethnicity correction
factor of 1.210 is established for African ethnic in this equation due to their
difference of body composition, diet and muscle mass from American or Asian
(Devaney and Tomson, 2006; Perazella and Reilly, 2003).
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3.4.3 Haematological tests
The full blood count (FBC) was determined for each patient. However, our main
interest was in the assessment of the CD4 cell count, which indicates the immuno-
competence level.
3.4.4 Sputum microbiological test
The sensitivity test for MTB was identified in the sputum of patients for each of the
second-line anti-TB drugs, before the start of the treatment. At BCH, the second line
anti-TB drugs used are: kanamycin, pyrazinamide, ethionamide, ethambutol,
capreomycin, para amino salicylic acid and terizidone.
3.4.5 HIV test
HIV-test (ELISA) and viral load level were performed for each patient after patients
were provided with pre and post-test counselling regarding the HIV-test.
3.5 Study procedures
3.5.1 Demographic, clinical and therapeutic characteristics
After inclusion into the study, the demographic, clinical and therapeutic (drug
history) characteristics were recorded for each patient. They were captured on a
computer-spreadsheet designed for this study.
3.5.2 Ofloxacin administration
Patients received ofloxacin tablets orally at a daily dose of 800 mg. On the study day,
after 8 hours overnight fast, ofloxacin was given to each patient with water at 7 a.m.
They were allowed to have breakfast 30 minutes after ofloxacin ingestion. Lunch
was served at 12 noon and dinner at 6 p.m.
3.5.3 Blood sampling for ofloxacin plasma concentrations
Blood samples were taken after two week of treatment, to allow ofloxacin steady state
to be attained. For the measurement of ofloxacin plasma concentrations, 5 ml of blood
was taken before ofloxacin administration (baseline), and then at 1, 2, 4, 8 and 24
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hours after ofloxacin administration (post-dose). Blood samples were collected from a
heparinized intravenous catheter fixed on a forearm vein of each patient before taking
the dose. All blood samples were drawn and placed into vacuum tubes and
immediately centrifuged at 3000 rpm for 5 minutes. The plasma was separated and
stored at -80 ˚C until the day of analysis.
3.6 Determination of ofloxacin plasma concentrations
In this study, ofloxacin levels in the plasma were determined using liquid
chromatography/mass spectrometry at Stellenbosch University, central analytical
facility (LC/MS laboratory) in Stellenbosch; Cape Town; South Africa.
3.6.1 Chemicals
The following chemicals were used in the study:
Analytical grade dimethyl sulfoxide (DMSO), acetonitrile (ACN), trichloroacetic
acid (TCA), phosphoric acid and HPLC grade trifluroacetic acid (TFA) were
obtained from Sigma-Aldrich (Cape Town, Western Cape). Ofloxacin tablets
(Zanocin 200mg, Ranbaxy Pty Ltd, SA) were supplied by BCH and used as working
standard.
3.6.2 Chromatographic and mass spectrometric conditions
3.6.2.1 Column liquid chromatography
The liquid chromatography was performed with Waters 2695 HPLC system (Waters,
Microsep Pty Ltd). The column utilized was a polar C18 liquid chromatography
column, Waters Atlantis™ (5µm, 2.1mm x 100mm) at ambient temperature. The
mobile phase used was 0.1% TFA at a flow rate of 0.20 ml/min and an injection
volume of 5 µl.
3.6.2.2 Mass spectrometry setting
The instrument used was Waters API Quattro Micro triple quadrupole mass
spectrometer with electrospray ionization (Waters, Microsep Pty Ltd). The ion source
and desolvation temperature were held at 120°C and 400 °C, respectively. The
capillary voltage was 3.7 kV, RFI 40. The desolvation gas at 550L/h and the cone
gas was 50 L/h. The daughter ion mass to ratio (m/z) for ofloxacin quantification was
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318 at collision energy 25 eV, and m/z for qualification was 261 at collision energy
30 eV as shown in Table 3.1. Waters Mass Lynx™ software was used for the data
collection, integration and calibration.
Table 3.1: Mass to charge ratio (m/z) of ofloxacin
Parent
(m/z)
Daughter (m/z),CE Daugther2 (m/z),CE Cone
voltage
Mode
362.5 318, 25 261, 30 20 +
CE: Collision Energy
3.6.3 Ofloxacin stock solution and calibration standard preparation
3.6.3.1 Preparation of stock solutions
Ofloxacin stock solution was prepared at a concentration of 1 mg/ml. The stock
solution was prepared by dissolving a 200 mg ofloxacin tablet in 50 ml DMSO, and
then it was further diluted using acetonitrile to obtain the final concentration of 1
mg/ml. The stock solution of 1 mg/ml was serially diluted with acetonitrile to get
working solutions with the concentrations 10, 5, 1, 0.5, 0.1 and 0.05 µg/ml.
3.6.3.2 Preparation of calibration standards
Ofloxacin plasma calibration standards were prepared by spiking blank plasma with
ofloxacin working solutions (with the concentrations 10, 5, 1, 0.5, 0.1 and 0.05
µg/ml). Ofloxacin was extracted from the plasma using acidic extraction similar to
the method reported by Zendelovska and Stafilov (2005), which is described as
follows:
A 500 µl plasma sample was diluted using 100 µl of 0.1M phosphoric acid and 300
µl of 5M trichloroacetic acid-acetonitrile (1:1, V/V) solution. The mixture was
vortex-mixed and then diluted again using 100 µl of acetonitrile and 300 µl of water.
The final solution was vortexed and centrifuged at 10000 g for 10 minutes. The
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supernatant collected and injected onto the liquid chromatography column for
analysis.
3.6.4 Patient samples preparation
To prepare the patients plasma samples for the LC/MS assay:
100 µl of 0.1M phosphoric acid and 300 µl of 5M trichloroacetic acid-acetonitrile
(1:1, V/V) solution were added to 500 µl of plasma, and the mixture vortexed well.
Then 100 µl of the internal standard was added and the mixture vortexed, and
centrifuged at 10000 g for 10 minutes. The supernatant was removed and injected
onto the liquid chromatography column for analysis.
To validate the assay the linearity, recovery, lowest limit of detection, lowest limit of
quantification, specificity, accuracy and precision were determined.
3.7 Determination of ofloxacin pharmacokinetic parameters
After determination of ofloxacin plasma concentrations, the plasma concentration-
time profile for each patient was plotted using GraphPad Prism program. Ofloxacin
pharmacokinetic parameters were calculated based on the non-compartmental
analysis (NCA) as follows:
3.7.1 The maximum concentration and the time to reach maximum
concentration
The maximum concentration (Cmax) and the time to reach the maximum
concentration (Tmax) were obtained directly from the plasma concentration-time
profile.
3.7.2 The elimination rate constant
The elimination rate constant (Ke) was calculated as the slope of terminal log-linear
phase of the plasma concentration-time profile multiplied by -2.303
3.7.3 The half-life
The half-life (T½) was calculated using the formula:
T½ = 0.639/Ke
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3.7.4 The area under the plasma concentration-time curve
The area under the plasma concentration-time curve from zero to 24 hours (AUC0-24)
was calculated by the trapezoidal method using GraphPad Prism software.
The area under the plasma concentration-time curve from zero to infinity (AUC0-∞)
was calculated using the following formula:
AUC0-24 + Cp last/ Ke
Where Cp last is the last measurable plasma concentration.
3.7.5 The volume of distribution
The following formula was used to determine the volume of distribution (Vd)
Vd = Dose/ (AUC0-∞ x Ke)
3.7.6 The total body clearance
The total body clearance (Cltot) was calculated using the following formula:
Cltot =Dose / AUC0-∞
3.7.7 The mean residence time
The mean residence time (MRT) was calculated as:
MRT= AUMC∞/AUC∞
Where AUMC∞ is the area under the momentum curve from zero to infinity and it
was calculated as
AUMC∞ = AUMC+ Clast/Ke+ ( tlast x Clast)/ Ke
AUMC is the area under the momentum curve and calculated using the following
equation
AUMC= (tici+ti-1 x ci-1)/2 x (ti-ti-1)
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3.8 Statistical analysis of the data
Patients data collected during the study was organised and coded onto data collection
forms before being captured into computer files. Microsoft Excel for windows was
utilised for computer management of the data, which was reported as mean ±
standard deviation (SD). Ofloxacin concentrations and pharmacokinetic parameters
were analyzed with the use of descriptive statistics mean ± SD.
3.9 Ethical consideration
The study was conducted according to the declaration of Helsinki and ICH
guidelines. The protocol was approved by the ethics committee of the University of
the Western Cape. Permission to conduct the study was granted by the medical
superintendent of BCH. HIV test informed consents were used and all the
information obtained during the study was treated as confidential.
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CHAPTER FOUR
RESULTS AND DISCUSSION
4.1 Ofloxacin LC/MS analysis method validation
A liquid chromatography/mass spectrometric method for the determination of
ofloxacin in human plasma was developed and validated. The validation of ofloxacin
LC/MS analysis was conducted by determining linearity, recovery, precision and
accuracy, low limit of detection, low limit of quantification and specificity.
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4.1.1 Calibration curve and linearity
The calibration curve was constructed by plotting the responses (peak areas) of
ofloxacin against the corresponding concentrations. Figure 4.1 shows the
concentrations of the calibration standards of ofloxacin (in µg/ml) on the x-axis. The
response (peak areas) is shown on the y-axis of the same figure. The calibration
curve was linear over the range (0.1-10 µg/ml) as shown in Figure 4.1. The
correlation coefficient (r²) of determination of ofloxacin during the validation was
greater than 0.99.
Figure 4.1: Ofloxacin calibration curve.
Compound name: Ofloxacin
Correlation coefficient: r^2 = 0.997987
Calibration curve: 118.774 * x + -3.69964
Response type: Calibration Std, Area
Curve type: Linear.
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4.1.2 Recovery
Ofloxacin recovery was determined by comparing peak areas from the plasma
samples that spiked with ofloxacin after extraction (i.e. calibration standards) with
the corresponding ofloxacin standard solutions. The mean recovery of ofloxacin was
97.6 ±1.6%.
4.1.3 Precision and accuracy
Acceptable precision and accuracy were achieved. The overall precision expressed as
relative standard deviation (R.S.D %), was less than 10%. The accuracy, expressed in
terms of recovery was found to range from 98.7% to 98.8% for 1 µg/ml and 92.5% to
100.5% for 10 µg/ml.
4.1.4 Lower limit of detection and quantification
The lower limit of detection of ofloxacin concentration that could be determined
(taking into consideration the concentration which produces a signal to ratio of 3 that
gives a measurable response from the MS detector) was 0.05 µg /ml. Ofloxacin
lower limit of quantification in the plasma was found to be 0.1 µg /ml.
4.1.5 Specificity
There are no interfering peaks from the plasma components with ofloxacin peak,
which was detected at a retention time of 9.68 minutes. Chromatograms showing the
separation of ofloxacin standard and ofloxacin plasma extract (calibration standard)
in addition to the blank plasma are shown in Figure 4.2.
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(A) Chromatogram of ofloxacin standard.
(B) Chromatogram of ofloxacin plasma extract (calibration standard).
Time
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(C) Chromatogram of blank plasma
Figure 4.2: Chromatograms of ofloxacin representing the separation of ofloxacin
at retention time 9.6 minutes. (A) Ofloxacin standard; (B) Ofloxacin calibration
standard, (C) Blank plasma.
Based on all the afore-mentioned findings, the method developed was linear,
sensitive, specific, precise and accurate. Therefore, it is suitable for the quantitative
analysis of ofloxacin in present study.
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4.2. Patients demographic data and characteristics
Eight patients (black) with multi-drug resistant pulmonary tuberculosis participated
in the study. The patient’s demographic data, which are body weight in kilograms,
age in years and gender, are listed in Table 4.1.
Table 4.1: Patients’ demographic data
Patient Weight (kg) Age (years) Gender
1 60 22 Female
2 59.3 46 Male
3 46.7 50 Male
4 55.5 31 Male
5 43.4 38 Male
6 45 18 Male
7 61.8 42 Female
8 46.6 18 Female
Mean 52.2 33.1 ___
SD 7.6 12.7 ___
The patients were given the drugs to which MTB had been found to be sensitive.
Anti-TB drugs used with their doses and other co-existing diseases are shown in
Table 4.2.
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Table 4.2: Anti-TB drugs, other medications and co-existing diseases
Patient Co-existing
disease
Ofloxacin
(Daily dose)
Co-administered anti-TB drugs
(Daily dose)
Other
medications
1 HIV 800 mg
KAN (1gm), EMB (1.2 gm)
, PZA (1.5 gm), ETH (750 mg),
d4T (30mg),
3TC (150mg),
EFV (600mg)
2 HIV/HBV 800 mg
KAN (1gm), PZA (1.5 gm), ETH (750 mg)
d4T (30mg),
3TC (150mg),
EFV (600mg)
3 HIV
800 mg
KAN (750 mg), EMB (800mg), PZA
(1gm),
ETH (500mg)
_
4 HIV 800 mg
KAN (1gm), EMB (1.2 gm), PZA (1.5 gm),
ETH (750 mg)
_
5 HIV 800 mg
KAN (750 mg), EMB (800mg), PZA
(1gm),
ETH (500mg)
d4T (30mg),
3TC (150mg),
EFV (600mg)
6
___
800 mg
KAN (750 mg), EMB (800mg), PZA
(1gm),
ETH (500mg)
_
7 HBV/DM 800 mg
KAN (1gm), EMB (1.2 gm), PZA (1.5 gm),
ETH (750 mg)
_
8
___
800 mg
KAN (750 mg), EMB (800mg), PZA
(1gm),
ETH (500mg)
_
DM=Diabetes mellitus; HBV= Hepatitis B virus; ETH=ethionamide;
EMB=ethambutol; KAN=kanamycin; PZA=pyrazinamide; d4T= stavudine;
3TC = lamivudine; EFV =efavirenz
All drugs were given orally except kanamycin which was given intramuscularly.
Patients’ mean (±SD) age and weight were33.31±12.75 years and 52.28±7.6 kg
respectively. The ofloxacin daily dose was 800 mg taken with kanamycin,
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pyrazinamide, ethambutol and ethionamide. Five patients were HIV-positive; two
patients have hepatitis-B and one patient was diabetic. Patients, who were co-
infected with HIV (except patient 3 and 4), were on the following anti-retroviral
drugs: stavudine (30 mg), lamivudine (150 mg) and efavirenz (600 mg).
Table 4.3 shows the laboratory-test results of CD4 cell count (for patients co-infected
with HIV), kidney function test results as glomerular filtration rate, and liver
enzymes (ALT, AST and GGT) and UCB levels.
Table 4.3: Laboratory-tests results
GFR= glomerular filtration rate; GGT= gamma glutamyl transpeptidase; ALT=
alanine aminotransferase; AST= aspartate aminotransferase; UCB=un-conjugated
bilirubin
PatientTest Normal
range
1 2 3 4 5 6 7 8 Mean SD
CD4
Cell count
(cell/mm3)
700-1100 15
5
53 137 48 327 _ _ _ 144 113.09
GFR
(ml/min) >90 69 116 70 128 136 142 91 122 109 28.89
GGT
(u/l) 5-50 87 253 30 101 30 19 22 5 68.37 81.98
ALT
(u/l) 10-40 54 64 71 32 14 21 18 1 34.37 25.60
AST
(u/l) 10-40 13
2
137 114 54 67 34 18 44 75 46.31
UCB
(µmol/L) 2-14 16 12 22 4 9 8 5 37 14.12 10.97
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The CD4 cell counts mean (±SD) for the patient co-infected with HIV was
144±113.09 cell/mm3, whereas the mean (±SD) of GFR rate for all patients was
109±28.89 ml/min. Regarding the liver enzymes results, the mean (±SD) of ALT
and AST were 34.37±25.60 u/l and 75±46.31 u/l respectively. The mean (±SD) of
GGT is 68.37±81.98 u/l and for UCB was 14.12±10 µmol/L.
4.3 Ofloxacin plasma concentrations and pharmacokinetic parameters
4.3.1 Ofloxacin plasma concentrations
Ofloxacin plasma concentrations at different time points after ofloxacin
administration, over 24 hour’s period are listed in Table 4.4. There are some
patients with no concentration results at 1 and 2 hours because the sample tubes
were broken during the centrifugation. Patients with missing 24 hour’s
concentrations left the hospital before their blood samples were taken.
Table 4.4: Ofloxacin plasma concentrations
Time (hours) after ofloxacin administration
Patient
Baseline
(0 hr)
(µg/ml)
1 hr
(µg/ml)
2 hrs
(µg/ml)
4 hrs
(µg/ml)
8 hrs
(µg/ml)
24 hrs
(µg/ml)
1 3.53 2.73 2.84 7.87 7.51 4.13
2 BDL NA 3.90 5.24 3.34 0.73
3 BDL NA 2.46 3.11 3.80 NA
4 BDL 4.95 4.50 4.44 3.35 1.22
5 BDL 5.50 6.85 6.16 4.68 1.87
6 BDL 0.86 1.32 2.98 2.54 0.51
7 BDL 2.68 NA 3.90 2.65 NA
8 1.17 0.82 0.96 1.20 0.63 0.62
Mean 2.35 2.92 3.26 4.36 3.56 1.51
SD 1.66 1.97 2.02 2.07 1.98 1.37
NA= not available.
BDL= below detectable level (0.05 µg/ml)
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Ofloxacin plasma concentration-time profiles for each patient and mean (±SD)
plasma concentration-time profile for all patients are shown in Figures 4.3 and 4.4
respectively.
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Figure 4.3: Ofloxacin plasma concentration-time profile for each patient.
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Figure 4.4: Ofloxacin mean (±SD) plasma concentration-time profile for all
patients.
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4.3.2 Ofloxacin pharmacokinetic parameters
Table 4.5 shows ofloxacin pharmacokinetic parameters in patients, who had been on
treatment for two weeks. The parameters were calculated using the NCA method.
The pharmacokinetic parameters for all the patients were expressed as mean (±SD).
The range (minimum value-maximum value) for each parameter is also given. The
PK parameters for patient 3 were excluded, as ofloxacin concentration at the
elimination phase could not be estimated due to the 24 hour missing sample.
As reflected in Table 4.5, the mean (±SD) obtained for Cmax, Tmax, T½, Ke, MRT, Vd,
CLtot, AUC0-24 and AUC0-∞ were4.7±2.27 µg/ml, 3±1.29 hr, 9.55±4.69 hr, 0.08 ±
0.04,15.12±6.59 hr, 2.77 ± 1.1624 L/kg, 0.27 ± 0.25 L/hr/kg, 68.8 ± 42.61 µg/ml.hr
and 91.9 ± 76.8 µg/ml.hr respectively. Related data from other studies in addition to
the present one are included in Table 4.6 for comparison.
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Table 4.5: Ofloxacin pharmacokinetic parameters
Pharmacokinetic parameters
Patient Tmax
(hr)
Cmax
(µg/ml)
AUC0-24
(µg/ml.hr)
Ke T½
(hr)
MRT
(hr)
AUC0-∞
(µg/ml.hr)
Cltot
(L/hr/kg)
Vd
(L/kg)
1 4 7.87 137.4 0.037 18.54 29.14 249.22 0.053 1.44
2 4 5.24 58.86 0.095 7.28 11.2 66.54 0.2 2.13
4 1 4.95 65.81 0.064 10.81 10.7 84.87 0.17 2.68
5 2 6.85 93.27 0.059 11.74 17 125.51 0.14 2.49
6 4 2.98 41.16 0.100 6.90 11.1 46.26 0.28 2.88
7 2 3.90 *NA 0.097 7.17 12 50.57 0.24 2.6
8 4 1.2 16.71 0.161 4.38 14.7 20.56 0.83 5.18
Mean 3 4.71 68.8 0.08 9.55 15.12 91.9329 0.27329 2.77143
SD 1.29 2.27 42.61 0.04 4.69 6.59632 76.8682 0.25606 1.1629
Range 1-4 1.2-7.87 16.71-140.5 0.037-0.16 4.38-18.54 10.7-29.14 20.56-249.22 0.053-0.83 1.44-5.18
Cmax = maximum plasma concentration, Tmax = time to attain Cmax; T½ = elimination half-life; AUC0-24 = area under the concentration-time curve from zero to
24 hrs; AUC0-∞= area under the plasma concentration-time curve from zero to infinity Cltot = total plasma clearance; Vd = volume of distribution; Ke =
elimination rate constant; MRT = mean residence time.*For patient 7, the AUC0-24 is not available, as the last plasma concentration available was at 8 hrs.
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Table 4.6: Ofloxacin pharmacokinetic parameters obtained in the present study and in previous studies.
Cmax = maximum plasma concentration, Tmax = time to attain Cmax; T½ = elimination half-life; AUC0-24 = area under the concentration-time curve from zero
to 24 hrs; AUC0-∞= the area under the plasma concentration-time curve from zero to infinity; Cltot = total plasma clearance; Vd = volume of distribution; Ke =
elimination rate constant, NA= not available.
Study
conditions
Dose
(mg)
Cmax
(µg/ml)
Tmax
(hr)
T ½
(hr)
Ke
AUCo-24
(µg/ml.hr)
AUCo-∞
(µg/ml.hr)
Vd
(L/kg)
Cltot
(L/hr/kg)
Reference
TB
patients
800
(600-1000)
10.5
(8-14.3)
1.03
(0.5-6)
7.34
(3.53-28.3)
0.094
(0.025-0.196)
NA NA
1.28
(0.78-
2.83)
0.12
(0.02-0.32)
Zhu et al.,
2002
MDR-TB
patients
590.9 9.61±2.17 1.68±1.21 8.03±3.37 NA 70.57±26.4 82.45±43.64 1.37±0.24 NA
Chulavatnatol
et al.,2003
Healthy
volunteers 800
9.8
(8.2-11.4)
1.9
(1.6-2.2)
6.5
(6.1-6.9) NA
85.3
(69.4-101.2)
93.1
(79.7-106.5)
NA NA
Immanuel
et al.,2002
Present
study
800 4.71±2.27 3±1.29 9.57±4.69 0.08±0.04 69.55±42.93 92.54±77.69
(21.63-252.12)
2.73±1.12 0.26±0.24 _
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4.4 Discussion
4.4.1 The LC/MS analysis method
In this study, LC coupled with MS was used for the determination of ofloxacin
concentrations in patients’ plasma samples. The MS settings used (Table 3.1) similar to
those with that previously reported in the literature, which provide high sensitivity,
specificity, selectivity and rapid determination of ofloxacin in biological samples (van
Vyncht et al., 2002; Ballesteros et al., 2003; Sinnaeve et al., 2003).
Good separation of ofloxacin at 9.6 minutes as a retention time with a high recovery
percentage (97.6%) was obtained. Under the described chromatographic conditions,
ofloxacin peak was well resolved and endogenous plasma components did not interfere
with ofloxacin peak as indicated in the chromatogram (Figure 4.2, B). This revealed high
specificity of the analysis method.
In summary, although other ofloxacin PK studies have used other HPLC methods coupled
with UV or fluorescence detection, our validation results indicate that the LC/MS analysis
method is successful and able to detect and quantify ofloxacin in plasma.
4.4.2 Demographic characteristics and concomitant infections
The numbers of patients in this study (8) (5 male and 3 female) close to the patients’
numbers involved in other similar studies. The study conducted by Chulavatnatol et al.
(2003) had11 patients (8 males and 3 females). Zhu et al. (2002) had 11 patients (9 males
and 2 females) and Immanuel et al. (2002) study had7 patients (all males). The relatively
small number of patients was due to the difficulty in obtaining consent from patients with
HIV and TB. Most of the patients were also severely sick, and their inclusion in the study
would have been unethical, even if they gave consent.
The mean age and weight of study group (33.12 yrs and 52.28 kg respectively), were
comparable to those reported in the studies done before. For example, the mean age and
weight of the patients in Chulavatnatol et al. (2003) study were 38.09 yrs and 59.34 kg
respectively. For the study, which was done by Zhu et al. (2002), the mean age was 42 yrs;
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and the mean weight was 64 kg. In the study conducted by Immanuel et al. (2002), the age
and the weight were 34.5 yrs and 59.2 kg respectively.
Although 5 patients were co-infected with HIV, no other opportunistic infections present
except MDR-TB and HBV was found in one patient only.
4.4.3 Laboratory results
The GFR is the best indicator for the kidney functions, as the kidney dysfunction stages
can be evaluated using the GFR value. Stages of kidney function range from normal
kidney function with a GFR more than 90 ml/min to renal failure where the GFR is less
than 15 ml/min. In this study, 6 out of 8 patients (75%) had normal kidney function. Three
out of the six patients were HIV-positive with CD4 cell counts 53, 48, and 327cell/mm3.
Two patients had mild decrease in their GFR values (60-89 ml/min). Therefore, they are
classified as presenting mild renal failure. Both patients were HIV-positive with a CD4
cell counts 137 and 155 cell/mm3.
With regard to the liver enzymes levels, the mean ALT value was within the normal range,
however, some patients had abnormal levels. On the other hand, the AST and GGT mean
values were above the upper limit of the normal range and the UCB levels within the
normal range. Three patients had mild elevations in both ALT and AST (less than 5 times
the upper limit of normal value, which is 200 u/l). Regarding GGT, three patients had high
levels of this enzyme. One patient was co-infected with hepatitis and this might explain the
patient’s abnormal liver enzymes level, especially the GGT, which its elevation is an
indicator of viral hepatitis. However, another patient is also co-infected with hepatitis, but
the liver enzymes level within the normal range.
ALT, AST and GGT liver enzymes are markers for liver injury and alcohol abuse. Many
conditions such as hepatitis, cirrhosis, drug-induced injuries and alcohol abuse can cause
the elevation of these enzymes level. However, abnormal levels of these enzymes do not
necessarily reflect how severely the liver is damaged (Giannini et al., 2005). The liver
enzymes levels for patients in this study indicate some sort of liver up normality. Co-
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infection with HBV explains this up normality in patient 2; however, for other patients it
might be due to alcohol abuse or other liver disease that is not apparent.
4.4 4 Ofloxacin pharmacokinetics
The Cmax and AUC0-24 results obtained in this study were lower than those reported in the
literature by Zhu et al. (2002) and Immanuel et al. (2002). The mean AUC0-∞ was similar
to that obtained by Immanuel et al. (2002) (Table 4.6). Furthermore, ofloxacin was
absorbed with a longer Tmax compared with that reported in the literature (Table 4.6).
These two parameters are higher than those reported in the literature (Table 4.6). In the
present study, ofloxacin T½ was longer than the one reported in previous studies (Table
4.6). Finally, Ke was similar to that reported by Zhu et al. (2002).
Ofloxacin has a high absorption rate and oral bioavailability more than 90%; therefore, its
peak serum concentration was achieved within 1-2 hours (Table 2.3). The pharmacokinetic
parameters of ofloxacin are dose independent; however, the absorbed amount increases
linearly with increasing dose, which leads to an increase in Cmax and AUC (Lode et al.,
1987; Immanuel et al., 2002). This explains why not comparing our Cmax, AUC0-24 and
AUC0-∞ with the values obtained in Chulavatnatol et al. (2003) study.
The low Cmax and low AUC0-24 in addition to the prolonged Tmax indicate a reduction in the
extent and the rate of ofloxacin absorption in our patients. Ofloxacin absorption may be
blocked by divalent cations included in nutritional supplements or antacid. Co-
administration of didanosine leads to a decrease of ofloxacin absorption and as a
consequence, its AUC decreases (Walker, 1999; Katzung, 1998; Goodman et al., 2005).
Furthermore, co-ingestion with food delays ofloxacin absorption and the time to reach Tmax
by an hour (Walker, 1999; Katzung, 1998). This suggests the influence of food or drug
co-administration effect on ofloxacin absorption. None of our patients is taking a
nutritional supplement or antacid, however, we cannot control the food intake in our
patients. Another factor that could lead to long Tmax is delayed gastric-emptying
phenomenon, due to taking efavirenz by patients co-infected with HIV (Villani et al.,
2001). This may explain the long Tmax observed in patients 1 and 2 who were on ARVs
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including efavirenz. Although, patient 5 was also taking efavirenz, he had a normal Tmax,
and this can be explained by inter-individual variations.
Impaired liver function may lead to significant alterations in the PK of many drugs, which
are metabolized in the liver. Ofloxacin is a poorly metabolized drug, however, a reduction
in Cmax, AUC and prolonged Tmax and T½ have been reported (Verbeeck and Horsmans,
1998; Wang et al., 2006). This indicates that the PK parameters of ofloxacin may be
influenced by liver dysfunction. The liver enzymes levels in patients showed that some
form of liver disease was likely in patients, which may explain the low Cmax, low AUC0-24,
prolonged Tmax and the long T½.
Ofloxacin has a high volume of distribution associated with its low protein binding (<
30%) (Katzung, 1998; Walker, 1999). Ofloxacin high Vd in the present study reflects that
ofloxacin has higher concentration in the extra-vascular tissues than in the vascular parts,
which means it is not homogenously distributed. Although the high Vd may contribute to
the low Cmax and the long T½ in patients, the high Vd cannot be related to the high Cltot, as
the extent of a drug distribution is independent of its clearance (Mehvar, 2004). Patients
have a high elimination rate which is consistent with the high Cltot value. The low AUC0-24
and low Cmax can be correlated with the high elimination rate. During the time that plasma
concentration is rising, the elimination process is also occurring, resulting in low Cmax
(Mehvar, 2004). This may also be associated with the low Cmax, long Tmax and the decrease
in AUC0-24 in this study, as patients have high Cltot compared with that reported.
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Ofloxacin is mainly cleared through the kidney and its elimination process decreases
progressively with renal impairment. With the decrease of the GFR, ofloxacin Ke and Cltot
decrease and this results in an increase of the T½ and AUC0-∞ (Fillastre et al., 1987;
Navarro et al., 1990). Ofloxacin T½ increases in relation to the degree of renal dysfunction
and can reach values five-fold higher than those obtained in normal subjects. However, the
high T½ in patients cannot be related to the renal dysfunction because the GFR of most
patients was within the normal range (Table 4.3). Prolonged T½ in the patients with the
normal GFR may be referred to the effect of their abnormal hepatic function on ofloxacin
metabolism. The low GFR for patient 1 explains the high AUC0-∞, long T½, long MRT and
low Cltot of that particular patient compared to the other patients. It may also explain the
high Cmax in the same patient.
The mean (±SD) MRT for patients is 15.12 ± 6.59 hrs and it was longer than that reported
by Chulavatnatol et al. (2003), which was 10.77±4.55 hrs. The long MRT is correlated
with the long T½ in study. This can be explained by the high Vd of ofloxacin in this group
of patients in addition to the abnormal liver functions.
In conclusion, ofloxacin pharmacokinetics was quite different in patients compared with
previously reported studies. Many factors could have contributed to the differences in
results as the genetic differences, and patients’ health conditions. Furthermore, the
different analytical method, which was used in the present study (LC/MS), should also be
mentioned in the consideration of the different pharmacokinetic parameters obtained
4.5 Therapeutic and clinical implications
From the published data, low serum concentrations of anti-TB drugs were associated with
acquisition of drug-resistant MTB, treatment failure and recurrence of TB (Berning et al.,
1992; Peloquin, et al., 1993; Patel at al., 1995). The Cmax and AUC values showed an
inadequate serum concentration of ofloxacin in patients compared with previous report.
The mean Cmax of ofloxacin in study was 4.71 µg/ml (with a Tmax of 3 hours), which was
lower than the optimal plasma concentrations level for TB treatment. The efficacy of
ofloxacin is correlated with the Cmax levels in plasma, and the target Cmax serum
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concentration of ofloxacin in TB patients that provides good treatment outcome is 8-12
µg/ml with a Tmax 1-2 hours (Root et al., 1999).
Ofloxacin low serum concentrations in the present study indicate that, patients may have
poor therapeutic response, which can lead to treatment failure, relapse and further drug
resistance (ofloxacin resistance/ XDR-TB). Therefore, we recommend monitoring
ofloxacin plasma concentrations and adjusting the current ofloxacin dose. The
optimization of ofloxacin dose may result in ofloxacin serum levels that reach the
therapeutic range and lead to the desired therapeutic effect and successful treatment.
4.6 Limitations of the present study
There are many patients with MDR-TB in the hospital where the study was conducted.
Within seven months, we managed to recruit 30 patients. However, 10 out of the 30
patients gave written consent and two patients of the 10 were excluded. This explains why
only 8 patients were involved. Furthermore, the number of 8 patients is low for a reliable
statistical analysis.
For the same reason as those mentioned above, it was difficult to get an equally high
balance of patients with MDR-TB on one side and patients with MDR-TB co-infected with
HIV on the other side for comparison.
It would be interesting to find out the influence of HIV and/or AIDS on the
pharmacokinetics of ofloxacin. However, the small patients’ number and the poor balance
of distribution of our patients within the different ranges of CD4 cell count did not allow
that assessment.
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CHAPTER FIVE
CONCLUSIONS AND RECOMMENDATIONS
5.1 Conclusions
The objectives of the present study were to determine ofloxacin plasma concentrations and
to evaluate the pharmacokinetics of ofloxacin in MDR-TB patients during their regular
course of treatment. For the quantification of ofloxacin in patients’ plasma, liquid
chromatography coupled with mass spectrometry was used as an analysis method.
The objectives of the present study were achieved, and based on the results obtained we
can conclude that:
 The LC/MS method used in the present study was simple, specific, accurate,
sensitive and reproducible. Therefore, it is suitable to quantify ofloxacin plasma
concentrations.
 This study found that, ofloxacin has a low rate and extent of absorption, which was
reflected in the long Tmax (3±1.29 hrs) and the low AUC0-24 (68.8±42.61 µg/ml.hr).
In addition, the peak plasma concentration of ofloxacin was low (4.71±
2.27µg/ml). Ofloxacin distributed widely (2.77±1.16 L/kg) and was eliminated
with high Cltot (0.27±0.25 L/hr/kg). The patients displayed a long T½ (9.55±4.69
hrs) and long MRT (15.12±6.59 hrs).
Due to the small number of patients and the patients’ different co-morbidities, we cannot
conclude whether the co-infection with HIV and impaired liver and kidney functions are
associated with the altered pharmacokinetic profile of ofloxacin in MDR-TB patients.
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5.2 Recommendations
This study provides information about the pharmacokinetics of ofloxacin in patients
infected with MDR-TB in South Africa; however, the number of patients used in this study
was small. Therefore, we recommend further studies with larger numbers of patients. We
also recommend investigating the effect of HIV/AIDS, liver dysfunction and kidney
dysfunction on ofloxacin pharmacokinetics. We also recommend using TDM for ofloxacin
in this group of patients to maintain constant ofloxacin concentration in their plasma.
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APPENDICES
Appendix A
Patient consent form (written consent only)
Patient study number: ……………………………
Patient statement
This study and related procedures have been explained to me to my satisfaction, I have
received a copy of the patient information sheet and have been given the opportunity to ask
questions which have been answered to my satisfaction. I hereby agree to voluntarily
participate in this program.
I understand that if I choose to withdraw from this study, I will need to inform my Doctor
in order to enable him to evaluate my status, to review the consequences of my decision, as
well as to allow him to perform procedures for an orderly termination of my participation.
………………………….. ………………………………….
Signature of patient Date (to be completed by patient)
Witness
……………………………..
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Statement of randomizing Doctor
I declare that I have explained to the above patient (name……, age …gender…..) the
nature, purpose, procedures, the possible risks and potential benefits of this research
project and have provided the patient with the patient information sheet whose reference is
( )*
(* Insert reference of Patient Information Sheet given to the patient)
……………………………….. ………………………
Signature of randomizing Doctor Date
Witness
…………………………………
Top Copy-patient‘s hospital notes Second Copy-patient Third Copy-Site Working
File
* Afrikaans and Xhosa copies of this form are available.
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Appendix B.1
Patient information sheet (for patients with TB)
Nature and purpose of the study
You have been found with multi-drug resistant pulmonary tuberculosis and infection due
to HIV. Tuberculosis is due to a bacterium which has affected your lungs and makes you
cough, get tired, lose weight, and present with the other symptoms you are complaining of.
Tuberculosis is a very common disease in the Western Cape. Under normal conditions, it
responds well to treatment. However, due to many factors including non-compliance with
the treatment, the number of patients infected by bacteria resistant to drugs usually used to
treat tuberculosis has dramatically increased.
Because of resistance to conventional anti-tuberculosis drugs used n short-course (6
months) chemotherapy, including streptomycin, isoniazid, rifampicin, pyrazinamide and
ethambutol, it has become necessary to use traditional second-line anti-tuberculosis (anti-
TB) drugs and newer anti-bacterial agents. The former include aminoglycosides (e.g.
kanamycin), glycopeptides such as capreomycin, thiomides (e.g. ethionamide and
prothionamide), cycloserine and para-amainosalicylic acid (PAS). The latter involve the
newer amino glycosides such as amikacin and aminosidine, as well as some
fluoroquinolones, and perhaps rifabutin and clofazimine.
The pharmacology of some of the second line anti-TB drugs is not well known.
The purpose of this study is to assess: the effect of your body on the drugs given to you
(pharmacokinetics) and the influence of HIV on the pharmacokinetics of the drugs you are
going to take. The information obtained will help in the development of therapeutic drug
monitoring in order to optimize drug therapy and improve patient outcome.
In this study, you will receive a treatment regimen, which is recommended in South Africa
for the treatment of multi-drug resistant tuberculosis. It includes kanamycin/ amikacin,
ofloxacin, ethionamide, ethambutol, pyrazinamide, terizidone/cycloserine, capreomycin
and para-amino salicylic acid (PAS).
If you agree to participate in the study, 2 weeks after commencement of the treatment, you
will be requested to fast the first night from midnight. On the following morning, an
intravenous line will be put on your arm for blood collection, just before administration of
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the above-mentioned drugs. Blood samples will be collected in appropriate tubes in the
following order:
1. Five (5) millilitres for liver and renal function.
2. Five (5) millilitres for haematological and virological tests.
3. Five (5) millilitres for assessment of plasma drug concentration before administration of
drugs, then at 1,2,4,8 and 24 hours after administration of drugs.
You are instructed to take only the treatment prescribed by doctors in the ward where you
have been admitted.
Risks and difficulties
No risks and difficulties are expected to occur. However, you may experience the
following adverse effects: systemic or cutaneous allergic reactions, hepatitis, skin rashes
and reddish coloration of the urine.
Benefits
During the days of hospitalization you will benefit from regular visits from the doctor,
regular advice on the treatment, a close supervision of drug intake and an optimum diet.
Alternatives
If you decide not to take apart, you will be treated like any other patient in the word. Your
normal treatment will in no way be affected by your refusal to participate in the study.
Consent, withdrawal and confidentiality
You do not have to take part or can end your involvement at any time. If your doctor feels
that it is not in your best interest to stay in the study he will stop participation.
You will be provided with pre- and post-test counseling regarding the test for antibodies to
HIV, by trained counselors. All information obtained during the study will be treated as
confidential. If you want to know anything else, your doctor will answer any question you
may have.
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Dissemination of research results
The research results will be disseminated through the following channels:
a.Final report to the sponsor of the study
b.Presentation at departmental levels at institutions involved: University of the
Western Cape, University of Stellenbosch and Cape Peninsula University of
Technology.
c.Class teaching: Medical, Pharmacy, Nursing and Dental studens.
d.Conference presentations at national and international levels
e.Local radio and local news papers
f. Publication in scientific journals
Your names will always be kept confidential.
Name of investigator.............................................................Tel..........
* Afrikaans and Xhosa copies of this form are available.
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Appendix B.2
Patient information sheet (for patients with HIV infection and TB)
Nature and purpose of the study
You have been found with multi-drug resistant pulmonary tuberculosis and infection due
to HIV. Tuberculosis is due to a bacterium which has affected your lungs and makes you
cough, get tired, lose weight, and present with the other symptoms you are complaining of.
HIV destroys your body’s immune system and this causes many opportunistic infections.
One of the most important infections is tuberculosis.
Tuberculosis is a very common disease in the Western Cape. Under normal conditions, it
responds well to treatment. However, since the advent of HIV and some other factors, its
prevalence has seriously increased and the level of recurrence and relapses of the treated
patients has increased. The number of patients infected by bacteria resistant to drugs
usually used to treat tuberculosis has dramatically increased.
Because of resistance to conventional anti-tuberculosis drugs used n short-course (6
months) chemotherapy, including streptomycin, isoniazid, rifampicin, pyrazinamide and
ethambutol, it has become necessary to use traditional second-line anti-tuberculosis (anti-
TB) drugs and newer anti-bacterial agents. The former include aminoglycosides (e.g.
kanamycin), glycopeptides such as capreomycin, thiomides (e.g. ethionamide and
prothionamide), cycloserine and para-amainosalicylic acid (PAS). The latter involve the
newer amino glycosides such as amikacin and aminosidine, as well as some
fluoroquinolones, and perhaps rifabutin and clofazimine.
The pharmacology of some of the second line anti-TB drugs is not well known.
The purpose of this study is to assess: the effect of your body on the drugs given to you
(pharmacokinetics) and the influence of HIV on the pharmacokinetics of the drugs you are
going to take. The information obtained will help in the development of therapeutic drug
monitoring in order to optimize drug therapy and improve patient outcome.
In this study, you will receive a treatment regimen, which is recommended in South Africa
for the treatment of multi-drug resistant tuberculosis. It includes kanamycin/ amikacin,
ofloxacin, ethionamide, ethambutol, pyrazinamide, terizidone/cycloserine, capreomycin
and para-amino salicylic acid (PAS).
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If you agree to participate in the study, 2 weeks after commencement of the treatment, you
will be requested to fast the first night from midnight. On the following morning, an
intravenous line will be put on your arm for blood collection, just before administration of
the above-mentioned drugs. Blood samples will be collected in appropriate tubes in the
following order:
1. Five (5) millilitres for liver and renal function.
2. Five (5) millilitres for haematological and virological tests.
3. Five (5) millilitres for assessment of plasma drug concentration before administration of
drugs, then at 1,2,4,8 and 24 hours after administration of drugs.
You are instructed to take only the treatment prescribed by doctors in the ward where you
have been admitted.
Risks and difficulties
No risks and difficulties are expected to occur. However, you may experience the
following adverse effects: systemic or cutaneous allergic reactions, hepatitis, skin rashes
and reddish coloration of the urine.
Benefits
During the days of hospitalization you will benefit from regular visits from the doctor,
regular advice on the treatment, a close supervision of drug intake and an optimum diet.
Alternatives
If you decide not to take apart, you will be treated like any other patient in the word. Your
normal treatment will in no way be affected by your refusal to participate in the study.
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Consent, withdrawal and confidentiality
You do not have to take part or can end your involvement at any time. If your doctor feels
that it is not in your best interest to stay in the study he will stop participation.
You will be provided with pre- and post-test counseling regarding the test for antibodies to
HIV, by trained counselors. All information obtained during the study will be treated as
confidential. If you want to know anything else, your doctor will answer any question you
may have.
Dissemination of research results
The research results will be disseminated through the following channels:
a. Final report to the sponsor of the study
b. Presentation at departmental levels at institutions involved: University of the
Western Cape, University of Stellenbosch and Cape Peninsula University of
Technology.
c. Class teaching: Medical, Pharmacy, Nursing and Dental student.
d. Conference presentations at the national and international level
e. Local radio and local news papers
f. Publication in scientific journals
Your names will always be kept confidential.
Name of investigator.............................................................Tel...........
* Afrikaans and Xhosa copies of this form are available.
 
 
 
 
